News
Flagship's AI-focused Generate Biomedicines files IPO
Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.
News
Grail multi-cancer test taps into Hims & Hers network
Grail has teamed up with telehealth company Hims & Hers to boost access to its recently filed Galleri blood test for cancer screening.
News
Eikon, Veradermics close IPOs, as Salspera joins queue
Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.
Oncology
A cancer treatment modality that prioritises QoL, with Ben Z...
Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
News
FDA knocks back AstraZeneca's self-injected lupus drug
FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
